Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PFKFB3 | Q16875 | 4/20 | 0.74 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.74 |
| ▸ | CYSLTR2 | Q9NS75 | 5/20 | 0.72 |
| ▸ | CYSLTR1 | Q9Y271 | 5/20 | 0.72 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.68 |
| ▸ | LMNA | P02545 | 5/20 | 0.68 |
| ▸ | MAPT | P10636 | 3/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.58 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.58 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.58 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.58 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.58 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.58 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.58 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.58 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10275157 | 1.00 | PFKFB3 (0.74) | PFKFB3HDAC6CYSLTR2CYSLTR1KDM4E | |
| SCHEMBL10309039 | 0.92 | PFKFB3 (0.81) | PFKFB3HDAC6CYSLTR2CYSLTR1KDM4E | |
| SCHEMBL10275355 | 0.92 | PFKFB3 (0.81) | PFKFB3HDAC6CYSLTR2CYSLTR1KDM4E | |
| SCHEMBL10309012 | 0.88 | PFKFB3 (0.74) | PFKFB3HDAC6CYSLTR2CYSLTR1KDM4E | |
| SCHEMBL10275052 | 0.88 | PFKFB3 (0.74) | PFKFB3HDAC6CYSLTR2CYSLTR1KDM4E | |
| SCHEMBL10275115 | 0.87 | PFKFB3 (0.72) | PFKFB3HDAC6CYSLTR2CYSLTR1KDM4E | |
| SCHEMBL10275508 | 0.87 | PFKFB3 (0.72) | PFKFB3HDAC6CYSLTR2CYSLTR1KDM4E | |
| SCHEMBL10275118 | 0.87 | PFKFB3 (0.72) | PFKFB3HDAC6CYSLTR2CYSLTR1KDM4E | |
| SCHEMBL10309026 | 0.87 | PFKFB3 (0.72) | PFKFB3HDAC6CYSLTR2CYSLTR1KDM4E | |
| SCHEMBL10309013 | 0.87 | PFKFB3 (0.72) | PFKFB3HDAC6CYSLTR2CYSLTR1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8557823-B2 | Family of PFKFB3 inhibitors with anti-neoplastic activities | ADVANCED CANCER THERAPEUTICS, LLC (US) | 2013-10-15 | — | — | US | claimed |
| US-12630638-B2 | Methods and compositions for diabetes treatment and β-cell regeneration | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-05-19 | — | — | US | disclosed |
| US-20250074989-A1 | METHODS AND COMPOSITIONS FOR TREATING PANCREATIC DISEASE | METANOIA BIO INC (US) | 2025-03-06 | — | — | US | disclosed |
| US-20240269124-A1 | METHODS AND COMPOSITIONS FOR TREATING NEUROLOGICAL CONDITIONS | METANOIA BIO INC (US) | 2024-08-15 | — | — | US | disclosed |
| US-20240269111-A1 | METHODS AND COMPOSITIONS FOR TREATING OCULAR NEOVASCULAR DISEASE | METANOIA BIO INC (US) | 2024-08-15 | — | — | US | disclosed |
| US-20240262916-A1 | METHODS AND COMPOSITIONS FOR TREATING CARDIOVASCULAR DISEASE | METANOIA BIO INC (US) | 2024-08-08 | — | — | US | disclosed |
| EP-4340897-A1 | METHODS AND COMPOSITIONS FOR TREATING PANCREATIC AND HEPATIC DISEASE | METANOIA BIO INC. (US) | 2024-03-27 | — | — | EP | disclosed |
| EP-4340835-A1 | METHODS AND COMPOSITIONS FOR TREATING CARDIOVASCULAR DISEASE | METANOIA BIO INC. (US) | 2024-03-27 | — | — | EP | disclosed |
| EP-4340836-A1 | METHODS AND COMPOSITIONS FOR TREATING NEUROLOGICAL CONDITIONS | METANOIA BIO INC. (US) | 2024-03-27 | — | — | EP | disclosed |
| EP-4340896-A1 | METHODS AND COMPOSITIONS FOR TREATING OCULAR NEOVASCULAR DISEASE | METANOIA BIO INC. (US) | 2024-03-27 | — | — | EP | disclosed |
| WO-2022245698-A1 | METHODS AND COMPOSITIONS FOR TREATING PANCREATIC AND HEPATIC DISEASE | METANOIA BIO INC. (US) | 2022-11-24 | — | — | WO | disclosed |
| WO-2022245697-A1 | METHODS AND COMPOSITIONS FOR TREATING OCULAR NEOVASCULAR DISEASE | METANOIA BIO INC. (US) | 2022-11-24 | — | — | WO | disclosed |
| WO-2022245711-A1 | METHODS AND COMPOSITIONS FOR TREATING NEUROLOGICAL CONDITIONS | METANOIA BIO INC. (US) | 2022-11-24 | — | — | WO | disclosed |
| WO-2022245702-A1 | METHODS AND COMPOSITIONS FOR TREATING CARDIOVASCULAR DISEASE | METANOIA BIO INC. (US) | 2022-11-24 | — | — | WO | disclosed |
| WO-2022040161-A1 | METHODS AND COMPOSITIONS FOR DIABETES TREATMENT AND BETA-CELL REGENERATION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-02-24 | — | — | WO | disclosed |
| WO-2017208174-A2 | METHODS OF TREATING DISEASE WITH PFKFB3 INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-12-07 | — | — | WO | disclosed |
| US-8557823-B2 | Family of PFKFB3 inhibitors with anti-neoplastic activities | ADVANCED CANCER THERAPEUTICS, LLC (US) | 2013-10-15 | — | — | US | disclosed |
| US-20120177749-A1 | FAMILY OF PFKFB3 INHIBITORS WITH ANTI-NEOPLASTIC ACTIVITIES | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2012-07-12 | — | — | US | disclosed |
| EP-1748987-A2 | 2-PROPENE-1-ONES AS HSP 70 INDUCERS | Torrent Pharmaceuticals Ltd (IN) | 2007-02-07 | — | — | EP | disclosed |
| WO-2005097746-A2 | 2-PROPENE-1-ONES AS HSP 70 INDUCERS | TORRENT PHARMACEUTICALS LTD (IN) | 2005-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120177749-A1 | FAMILY OF PFKFB3 INHIBITORS WITH ANTI-NEOPLASTIC ACTIVITIES | PFKFB3, PFKFB2, PFKFB1 | PFKFB3 1/4885HDAC6 910/4885CYSLTR2 4649/4885 |
| US-12630638-B2 | Methods and compositions for diabetes treatment and β-cell regeneration | IAPP, APP, SLC2A3 | PFKFB3 27/4885HDAC6 4256/4885CYSLTR2 2533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.